Search
Varicella zoster vaccine (recombinant)
go.drugbank.com/drugs/DB13924ApprovedInvestigationalOne of the most common complications associated with shingles is the development of Post-Herpetic Neuralgia (PHN), a persistant severe nerve pain that develops as a result of chronic pain from shingles … Recombinant zoster vaccine, manufactured as the product Shingrix by GlaxoSmithKline, is an adjuvanted non-live recombinant vaccine indicated for prevention of shingles.
Fospropofol
go.drugbank.com/drugs/DB06716ApprovedIllicitInvestigationalWithdrawnFospropofol is a water soluble prodrug and is converted to propofol in the liver. Fospropofol is a short acting hypnotic/sedative/anesthetic agent. … Fospropofol is a Schedule IV controlled substance in the United States under the Controlled Substances Act.
Curcuma aromatica root oil
go.drugbank.com/drugs/DB11301ApprovedThe wild ginger has been used as a cosmetic herbal where its rhizomes exhibit a distinct fragrance and color. … The major constituents of Curcuma aromatica root oil are reported to be camphor, curzerenone, α-turmerone, ar-turmerone and 1,8-cineole [A27219].
Viltolarsen
go.drugbank.com/drugs/DB15005ApprovedInvestigationalA related, albeit a less severe, form of muscular dystrophy known as Becker muscular dystrophy (BMD) is characterized by the production of shortened and partially functional dystrophin protein. … Duchenne muscular dystrophy (DMD) is an X-linked recessive allelic disorder characterized by a lack of functional dystrophin protein, which leads to progressive ambulatory, pulmonary, and cardiac function
Apadamtase alfa
go.drugbank.com/drugs/DB15164ApprovedInvestigational[A262076] Patients with cTTP have a severe deficiency of a plasma metalloproteinase called ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13), which is responsible … [A262071] Apadamtase alfa, sold under the brand name Adzynma (ADAMTS13, recombinant-krhn), was approved by the FDA in November 2023 for use as an enzyme replacement therapy in patients with cTTP.
Fruquintinib
go.drugbank.com/drugs/DB11679ApprovedInvestigationalThe first approach can be exemplified by [bevacizumab], a VEGF-A trap antibody. … Therefore, the advent of fruquintinib, a new generation of VEGFR inhibitors with a high kinome selectivity, demonstrated the feasibility of the small-molecule inhibitor approach.
Deuruxolitinib
go.drugbank.com/drugs/DB18847ApprovedInvestigationalDeuruxolitinib is a deuterated form of [ruxolitinib] that selectively inhibits Janus kinases (JAK) JAK1 and JAK2. … [L51083] Alopecia areata is an autoimmune condition that attacks the hair follicles and leads to unpredictable hair loss in the scalp and other areas of the body.
Gefitinib
go.drugbank.com/drugs/DB00317ApprovedInvestigationalActing in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. … Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer.
Nabiximols
go.drugbank.com/drugs/DB14011Investigationalisomer as [DB00470], or in a 1:1 formulation with CBD from purified plant extract as [DB14011]. … In Canada, Sativex® has received a Notice of Compliance (NOC) for use as an as adjunctive treatment for symptomatic relief of spasticity in patients with multiple sclerosis (MS) who have not responded
Nuvaxovid
go.drugbank.com/drugs/DB15810ApprovedInvestigationalNuvaxovid (NVX-CoV2373) contains a recombinant mutant S protein that is codon-optimized for baculovirus-mediated expression in Sf9 cells derived from _Spodoptera frugiperda_ together with a Matrix-M adjuvant … (Fractions A and C from _Quillaja saponaria_ extract).